Acorda’s pipeline includes several innovative therapies aimed at treating neurological disorders

Acorda’s pipeline includes several innovative therapies aimed at treating neurological disorders:A novel drug delivery system designed to provide rapid and efficient delivery of medication. INBRIJA is the first product to utilize ARCUS technology, offering an inhaled route of administration that provides rapid relief from off episodes in Parkinson’s disease.Acorda continues to invest in research and development, exploring new therapies and delivery methods to address unmet needs in neurology. Their pipeline includes potential treatments for other neurological conditions and novel formulations of existing therapies to improve efficacy and patient convenience. Acorda Therapeutics is deeply committed to the patient community. They engage with patients, caregivers, and advocacy groups to understand their needs and incorporate their insights into the development process. Acorda’s patient centric approach ensures that their therapies not only address the clinical aspects of neurological disorders but also consider the broader impact on patients’ lives.